Perspective Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• Perspective Therapeutics, Inc. showed a decrease of -50.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Perspective Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2010: $2.99 million | Q4 2010: $2.77 million | Q1 2011: $3.48 million | Q3 2011: $1.59 million | Q4 2011: $3.44 million | Q1 2012: $2.52 million | Q3 2012: $5.03 million | Q4 2012: $4.44 million | Q1 2013: $3.68 million | Q3 2013: $5.28 million | Q4 2013: $4.41 million | Q1 2014: $23.70 million | Q3 2014: $2.08 million | Q4 2014: $1.34 million | Q1 2015: $1.08 million | Q3 2015: $1.59 million | Q4 2015: $679.0 thousand | Q1 2016: $5.69 million | Q3 2016: $8.46 million | Q4 2016: $6.67 million | Q1 2017: $5.10 million | Q3 2017: $3.96 million | Q4 2017: $2.95 million | Q1 2018: $2.37 million | Q3 2018: $2.19 million | Q4 2018: $3.20 million | Q1 2019: $4.06 million | Q3 2019: $4.58 million | Q4 2019: $3.18 million | Q1 2020: $2.41 million | Q3 2020: $1.94 million | Q4 2020: $9.59 million | Q1 2021: $64.84 million | Q3 2021: $61.69 million | Q4 2021: $60.35 million | Q1 2022: $58.90 million | Q3 2022: $18.99 million | Q1 2023: $36.45 million | Q2 2023: $28.32 million | Q3 2023: $17.98 million | Q1 2024: $142.12 million | Q2 2024: $252.00 million | Q3 2024: $226.44 million | Q1 2025: $44.41 million | Q2 2025: $28.85 million | Q3 2025: $26.76 million.
• Over the full 16 years of available data (2011 to 2025), Perspective Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,350.1%.
• Historical annual values: Fiscal year 2025: $30.63 million | Fiscal year 2024: $61.58 million | Fiscal year 2023: $9.24 million | Fiscal year 2022: $20.99 million | Fiscal year 2022: $55.89 million | Fiscal year 2021: $63.83 million | Fiscal year 2020: $2.39 million | Fiscal year 2019: $5.33 million | Fiscal year 2018: $2.60 million | Fiscal year 2017: $5.93 million | Fiscal year 2016: $10.14 million | Fiscal year 2015: $5.23 million | Fiscal year 2014: $7.68 million | Fiscal year 2013: $2.90 million | Fiscal year 2012: $2.67 million | Fiscal year 2011: $2.11 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026